"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Akero Therapeutics Inc. (NASDAQ:AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced that ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

Hereditary amyloidosis is usually caused by inherited genetic mutations that cause abnormal amyloid proteins to build up and damage different organs in the body. Here’s what you need to know ...

Amyloidosis has “nonspecific” symptoms, meaning they can be the result of many medical conditions and problems, so identifying and diagnosing the disease is difficult. Here are the steps your ...

Localized amyloidosis is usually less serious than the systemic form. Diagnosis is also complicated by the fact that the symptoms of amyloidosis are similar to those seen in other conditions that ...

Treatment options have also been limited — Lousada, now CEO of the nonprofit Amyloidosis Research Consortium in Newton, Massachusetts, was fortunate to survive thanks to a stem cell transplant that is ...